Clinical Scorecard: Assessment of Risk-Adjusted Antithrombotic Strategies and 30-Day Clinical Outcomes Following Endoscopic Treatment for Non-Variceal Upper Gastrointestinal Bleeding: A Retrospective Cohort Analysis

At a Glance

Key Highlights

• Documented adherence to antithrombotic strategies linked to lower rebleeding rates.
• Rebleeding occurred in 5.2% of adherent patients versus 17.8% of non-adherent patients.
• NACE was 12.0% in adherent patients compared to 34.0% in non-adherent patients.
• Overall rebleeding rate was 9.2% within 30 days.
• Emphasis on multidisciplinary assessment over rigid resumption protocols.

Guideline-Based Recommendations

Diagnosis

• Early risk stratification and urgent diagnostic endoscopy are recommended.

Management

• Individualized, indication-specific decisions about antithrombotic therapy interruption and resumption.

Monitoring & Follow-up

• Documented strategy adherence should be monitored to improve clinical outcomes.

Risks

• Residual confounding and misclassification may affect outcomes due to reliance on clinical documentation.

Patient & Prescribing Data

150 distinct index admissions for NVUGIB

Adherence to a risk-based management framework correlates with fewer adverse events.

Clinical Best Practices

• Implement structured health-system pathways for managing NVUGIB.
• Ensure comprehensive documentation of antithrombotic management strategies.
• Promote multidisciplinary collaboration in acute care settings.

Related Resources & Content

• Study on antithrombotic management in NVUGIB